11:10 AM EDT, 05/01/2025 (MT Newswires) -- Illumina ( ILMN ) has entered a multiyear partnership with Ovation.io to develop a dataset with integrated clinical multiomic insights from 25,000 patients treated with glucagon-like peptide-1 therapies, the companies said Thursday.

The commercially available dataset is expected to help the pharmaceutical industry advance drug discovery and development, the companies said.

Under the agreement, Ovation.io will supply genome samples from its biobank, which will be sequenced by Illumina ( ILMN ), they said.

The initial phase of the collaboration prioritized developing datasets from patients with liver and chronic kidney disease, as well as those treated with GLP-1 receptor agonists. The companies intend to scale the GLP-1 dataset moving forward.

Price: 77.84, Change: +0.24, Percent Change: +0.31